

June 22, 2017

To the various Securities Commissions and similar regulatory authorities in Canada

Dear Sirs/Mesdames:

As required by subparagraph (6)(a)(ii) of section 4.11 of National Instrument 51-102, we have reviewed the change of auditor notice of InMed Pharmaceuticals Inc. dated June 16, 2017 (the "Notice") and, based on our knowledge of such information at this time, we agree with the statements (1.) to (2.) and we have no basis to agree or disagree with statements (3.) to (5.) contained in the Notice.

Yours very truly,



Anton, Bryson + Schindler Chartered Professional Accountants LLP